Your browser is no longer supported. Please, upgrade your browser.
ILMN Illumina, Inc. daily Stock Chart
Illumina, Inc.
IndexS&P 500 P/E45.29 EPS (ttm)6.51 Insider Own0.30% Shs Outstand147.93M Perf Week-2.86%
Market Cap43.64B Forward P/E41.57 EPS next Y7.10 Insider Trans-18.32% Shs Float146.56M Perf Month-2.51%
Income973.00M PEG2.34 EPS next Q1.57 Inst Own94.40% Short Float2.38% Perf Quarter0.34%
Sales3.46B P/S12.62 EPS this Y-5.10% Inst Trans0.57% Short Ratio3.49 Perf Half Y-3.14%
Book/sh30.20 P/B9.77 EPS next Y10.22% ROA13.70% Target Price333.85 Perf Year-13.12%
Cash/sh21.40 P/C13.78 EPS next 5Y19.38% ROE23.60% 52W Range263.30 - 380.76 Perf YTD-1.64%
Dividend- P/FCF63.15 EPS past 5Y44.40% ROI13.60% 52W High-22.52% Beta1.03
Dividend %- Quick Ratio6.10 Sales past 5Y18.60% Gross Margin69.30% 52W Low12.04% ATR8.43
Employees7300 Current Ratio6.80 Sales Q/Q6.30% Oper. Margin28.00% RSI (14)44.83 Volatility2.10% 2.61%
OptionableYes Debt/Eq0.25 EPS Q/Q12.20% Profit Margin28.10% Rel Volume0.73 Prev Close293.39
ShortableYes LT Debt/Eq0.25 EarningsOct 24 AMC Payout0.00% Avg Volume1.00M Price295.00
Recom2.00 SMA20-3.00% SMA50-0.84% SMA200-4.45% Volume735,500 Change0.55%
Oct-25-19Initiated Guggenheim Buy $350
Jul-30-19Downgrade Canaccord Genuity Buy → Hold $330 → $300
Jul-12-19Downgrade BofA/Merrill Buy → Underperform
May-30-19Initiated Wolfe Research Outperform
Jan-03-19Upgrade UBS Neutral → Buy
Oct-09-18Initiated UBS Neutral
Aug-07-18Upgrade Morgan Stanley Underweight → Equal-Weight
Jul-31-18Reiterated Canaccord Genuity Buy $330 → $340
Feb-05-18Upgrade Citigroup Neutral → Buy
Jan-31-18Upgrade First Analysis Sec Equal-Weight → Overweight $277
Jan-05-18Initiated BTIG Research Neutral
Jan-05-18Downgrade William Blair Outperform → Mkt Perform
Jan-02-18Upgrade Wells Fargo Market Perform → Outperform
Oct-25-17Upgrade Robert W. Baird Neutral → Outperform $184 → $228
Oct-23-17Upgrade Janney Sell → Neutral
Oct-23-17Upgrade Deutsche Bank Hold → Buy $195 → $250
Sep-26-17Resumed Goldman Neutral $200
Aug-07-17Upgrade Canaccord Genuity Hold → Buy $170 → $215
Aug-02-17Upgrade First Analysis Sec Underweight → Equal-Weight
Apr-26-17Reiterated Cantor Fitzgerald Neutral $155 → $170
Nov-09-19 04:18PM  Cramer Weighs In On Nike, Beyond Meat And More Benzinga
Nov-08-19 09:00AM  Lexent Bio Enters Partnership with Illumina to Develop an In Vitro Diagnostic Kit PR Newswire
12:00AM  Investing in IPOs is an easy way to lose money Financial Times
Nov-04-19 05:40PM  Edited Transcript of ILMN earnings conference call or presentation 24-Oct-19 9:00pm GMT Thomson Reuters StreetEvents
Oct-31-19 04:30AM  8 Undervalued Biotech Stocks to Watch Now Investopedia
Oct-28-19 03:26PM  Global Markets Advance Monday
09:15AM  S&P: 3 Weeks of Gains and 3 Points from a New Closing High Zacks
Oct-25-19 04:28PM  Consumer DNA Testing Hits The Skids And Takes Illumina Stock With It Investor's Business Daily -7.88%
03:10PM  Wall Street Jumps Friday
09:18AM  Illumina (ILMN) Beats Q3 Earnings Estimates, Raises View Zacks
08:03AM  Dow Jones Futures: Amazon Dives On Earnings, But This Dow Giant Signals Breakout Investor's Business Daily
Oct-24-19 05:45PM  Illumina (ILMN) Q3 Earnings and Revenues Beat Estimates Zacks
05:40PM  Illumina Stock Dips As Consumer Genomics Weighs On Quarterly Beat Investor's Business Daily
04:21PM  Genomic Behemoth Illumina Crushes Third-Quarter Sales, Profit Forecasts Investor's Business Daily
04:05PM  Illumina Reports Financial Results for Third Quarter of Fiscal Year 2019 Business Wire
12:13PM  Illumina Earnings, Revenue Beat in Q3
09:44AM  Does Illumina, Inc.'s (NASDAQ:ILMN) CEO Pay Matter? Simply Wall St.
Oct-17-19 10:34AM  Analysts Estimate Illumina (ILMN) to Report a Decline in Earnings: What to Look Out for Zacks
10:21AM  Can Sequencing Products Drive Illumina's (ILMN) Q3 Earnings? Zacks
Oct-16-19 05:38PM  Jerome Dodson's 3rd-Quarter New Buys
Oct-11-19 06:00AM  Illumina- Shining a Light on Gene Sequencing MoneyShow
Oct-10-19 08:42AM  QIAGEN Inks Deal With Illumina to Deliver NGS-Based IVD Kits Zacks
Oct-09-19 08:26PM  Do Hedge Funds Love Illumina, Inc. (ILMN)? Insider Monkey
08:37AM  Illumina (ILMN) Inks Deal to Commercialize NGS-Based IVD Kits Zacks
Oct-08-19 04:05PM  Illumina to Announce Third Quarter 2019 Financial Results on Thursday, October 24, 2019 Business Wire
03:16PM  Qiagens Results Are Hitting Health-Care Stocks. Heres What to Do Next.
09:45AM  Qiagen Shares Tumble Following Q3 Sales Warning, Sudden CEO Departure Benzinga
08:56AM  Qiagen Stock Plunges as CEO Departs, Sales Fall Short
07:11AM  The Daily Biotech Pulse: D-Day For Clinuvel, Qiagen Warns Of Q3 Shortfall, Prevail Announces Gene Therapy Collaboration Benzinga
Oct-07-19 04:07PM  QIAGEN and Illumina Partner to Deliver Sequencing-Based In-Vitro Diagnostic (IVD) Tests Business Wire
04:05PM  Illumina and QIAGEN Partner to Deliver Sequencing-Based In-Vitro Diagnostic (IVD) Tests Business Wire
Oct-01-19 03:32PM  Does Illumina (NASDAQ:ILMN) Deserve A Spot On Your Watchlist? Simply Wall St.
11:56AM  Illumina, Broad Institute Partner on Secondary Genomic Analysis Zacks
10:10AM  Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report? Zacks
Sep-30-19 08:55AM  Illumina and Broad Institute Announce Agreement to Co-Develop Genomic Secondary Analysis Tools Business Wire
Sep-25-19 05:45PM  Illumina (ILMN) Outpaces Stock Market Gains: What You Should Know Zacks
08:44AM  Illumina (ILMN) Inks Deal to Develop Distributable Test Kits Zacks
Sep-24-19 08:00AM  Adaptive Biotechnologies Enters Partnership with Illumina to Develop Distributable IVD Test Kits for clonoSEQ and immunoSEQ Dx GlobeNewswire
Sep-23-19 11:25AM  Illumina (ILMN) Gains on Product Pipeline, Global Footprint Zacks
11:13AM  The Zacks Analyst Blog Highlights: Target, Illumina, T-Mobile US, Xcel and Regeneron Zacks
08:55AM  Illumina Names Joydeep Goswami Senior Vice President of Corporate Development and Strategic Planning Business Wire
Sep-20-19 02:14PM  Top Research Reports for Target, Illumina & T-Mobile US Zacks
Sep-19-19 05:45PM  Illumina (ILMN) Stock Moves 0.72%: What You Should Know Zacks
Sep-13-19 05:45PM  Illumina (ILMN) Gains As Market Dips: What You Should Know Zacks
Sep-12-19 05:09PM  4 5-Star Companies to Consider as Dow Eclipses 27,000
08:55AM  Illumina Recommends Stockholders Reject Mini-Tender Offer by TRC Capital Corporation Business Wire
Sep-09-19 11:34AM  Illumina Banks on New Product Suite Despite Margin Woes Zacks
07:15AM  With 45% Earnings Growth, Did Illumina, Inc. (NASDAQ:ILMN) Outperform The Industry? Simply Wall St.
Sep-05-19 03:07PM  Probability 101: How Not to Be a Sucker Zacks
09:15AM  How Boulder biotech companies are putting Colorado on the gene-editing map American City Business Journals
Sep-04-19 05:50PM  Illumina (ILMN) Stock Sinks As Market Gains: What You Should Know Zacks
03:18PM  ETFs to Gain From the Booming Genomics Market Zacks
07:00AM  Merger or Not, Pacific Biosciences Needs to Deliver Motley Fool
Sep-03-19 05:46PM  Top-Performing Biotech ETFs YTD Zacks
Aug-28-19 05:45PM  Illumina (ILMN) Stock Sinks As Market Gains: What You Should Know Zacks
09:30AM  Why Is Illumina (ILMN) Down 5% Since Last Earnings Report? Zacks
Aug-25-19 09:00AM  My 3 Top Healthcare Stocks for Long-Term Investors Motley Fool
Aug-22-19 04:24PM  Andreas Halvorsen Keeps Buying Centene, DaVita
Aug-19-19 07:20AM  If You Had Bought Illumina (NASDAQ:ILMN) Shares Three Years Ago You'd Have Made 67% Simply Wall St.
Aug-16-19 05:41PM  Ag tech company Biome Makers gets $4 million in VC funding from Europe American City Business Journals
Aug-14-19 09:00PM  5 Top Cancer-Fighting Stocks to Buy Now Motley Fool
Aug-08-19 02:59PM  Disruptive Health Care ETF Is Good For Your Genes ETF Trends
Aug-06-19 03:45PM  The Top 5 Buys of the Eaton Vance Worldwide Health Sciences Fund
09:38AM  3 Keys to Investing in Next-Gen Healthcare Stocks InvestorPlace
Aug-05-19 07:15PM  Illumina Inc (ILMN) President and CEO Francis A Desouza Sold $903,750 of Shares
11:55AM  Here's Why Illumina Tumbled 18.7% in July Motley Fool
Aug-01-19 07:20PM  Acquisition Boosts Exact Sciences' Role in Cancer Diagnostics
Jul-31-19 05:30PM  Edited Transcript of ILMN earnings conference call or presentation 29-Jul-19 9:00pm GMT Thomson Reuters StreetEvents
08:15AM  5 Things Illumina's Management Just Said That You'll Really Want to Know Motley Fool
Jul-30-19 09:21AM  Illumina (ILMN) Q2 Earnings Beat Estimates, Margins Contract Zacks
06:41AM  Does The Data Make Illumina, Inc. (NASDAQ:ILMN) An Attractive Investment? Simply Wall St.
05:23AM  Illumina Inc (ILMN) Q2 2019 Earnings Call Transcript Motley Fool
Jul-29-19 10:45PM  Illumina Hits a Speed Bump in the Second Quarter Motley Fool
05:25PM  Illumina (ILMN) Beats Q2 Earnings and Revenue Estimates Zacks
04:48PM  Genomics Behemoth Dives On Mixed Report; 2019 Profit Guidance Lags Investor's Business Daily
04:26PM  Illumina stock declines after earnings, outlook MarketWatch
04:05PM  Illumina Reports Financial Results for Second Quarter of Fiscal Year 2019 Business Wire
12:12PM  Illumina Earnings inline, Revenue Misses In Q2
07:27AM  Q2 Earnings Preview For Illumina Benzinga
Jul-27-19 12:17PM  10 Biggest Medical Device Stocks Motley Fool
Jul-26-19 02:56PM  [video]Illumina Expected to Earn $1.34 a Share
Jul-24-19 12:33PM  Illumina, GW Pharmaceuticals, Paycom, Zscaler and Square highlighted as Zacks Bull and Bear of the Day Zacks
12:16PM  What to Expect from Illumina Earnings After Preliminary Results Tanked ILMN Stock Zacks
07:15AM  Bear of the Day: Illumina (ILMN) Zacks
Jul-23-19 10:17AM  Can Sequencing Products Drive Illumina's (ILMN) Q2 Earnings? Zacks
Jul-22-19 05:50PM  Illumina (ILMN) Outpaces Stock Market Gains: What You Should Know Zacks
10:31AM  Analysts Estimate Illumina (ILMN) to Report a Decline in Earnings: What to Look Out for Zacks
10:06AM  What Happens If Pacific Biosciences Isn't Acquired By Illumina? Motley Fool
Jul-19-19 12:13PM  Here's Why Pacific Biosciences Is Tumbling Today Motley Fool
Jul-18-19 11:26AM  Here's 2 Very Lucrative Trades From My New Trading Venture
09:30AM  EXEL or ILMN: Which Is the Better Value Stock Right Now? Zacks
Jul-16-19 02:00AM  Illumina Expands Genomics Accelerator to Cambridge, UK Business Wire
Jul-15-19 05:50PM  Illumina (ILMN) Stock Sinks As Market Gains: What You Should Know Zacks
09:31AM  Company News for Jul 15, 2019 Zacks
Jul-12-19 05:05PM  What Happened in the Stock Market Today Motley Fool -16.12%
04:29PM  Nasdaq Today: Amazon Prime Day; Facebook Settles With FTC InvestorPlace
04:25PM  S&P 500, Dow, Nasdaq close at record levels again as bulls bank on Fed rate cut MarketWatch
04:18PM  This Genomics Stock Just Lost A Breakout Why Analysts Still Like It Investor's Business Daily
04:16PM  4 Top Stock Trades for Monday:JNJ, SQ, ILMN, ACB InvestorPlace
03:46PM  4 Healthcare Stocks That Are Feeling Sick InvestorPlace
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array. The company also provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and noninvasive prenatal testing, as well as products support services. It serves genomic research centers, academic institutions, government laboratories, and hospitals; and pharmaceutical, biotechnology, and commercial molecular diagnostic laboratories, as well as consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. has a partnership with Lundbeck Foundation GeoGenetics Centre for exploring the relationship between the evolutionary history of select mental and neurological disorders and infectious pathogens; and an agreement with HTG Molecular Diagnostics, Inc. for the development of nuclease-protection-based RNA or DNA profiling tests. It operates in North America, Europe, Latin America, the Asia-Pacific region, the Middle East, and South Africa. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RAGUSA ROBERT PSVP, Global Quality & OpsNov 01Sale297.281,674497,64710,192Nov 05 04:18 PM
Dadswell CharlesSVP & General CounselNov 01Sale297.2819357,3755,069Nov 05 04:55 PM
Van Oene MarkSVP Chief Commercial OfficerNov 01Sale300.10625187,56313,584Nov 05 04:50 PM
Ronaghi MostafaSVP & CTOOct 15Option Exercise69.344,000277,36080,585Oct 17 04:46 PM
Ronaghi MostafaSVP & CTOOct 15Sale310.934,0001,243,71176,585Oct 17 04:46 PM
Van Oene MarkSVP Chief Commercial OfficerOct 01Sale304.84625190,52514,209Oct 03 04:26 PM
Dadswell CharlesSVP & General CounselOct 01Sale304.2212437,7235,262Oct 03 04:24 PM
Ronaghi MostafaSVP & CTOSep 16Option Exercise69.3410,000693,40086,585Sep 18 05:03 PM
Ronaghi MostafaSVP & CTOSep 16Sale300.5310,0003,005,32376,585Sep 18 05:03 PM
Dadswell CharlesSVP & General CounselSep 03Sale279.881,220341,4545,386Sep 05 04:29 PM
FLATLEY JAY TDirectorAug 28Sale283.413,300935,253262,733Aug 29 04:33 PM
Ronaghi MostafaSVP & CTOAug 15Option Exercise69.3410,000693,40086,585Aug 19 04:50 PM
Ronaghi MostafaSVP & CTOAug 15Sale285.5210,0002,855,20376,585Aug 19 04:50 PM
FLATLEY JAY TDirectorAug 14Sale288.363,300951,588266,033Aug 15 06:31 PM
OSTADAN OMEADSVP Mktg, Prod & Strat PlanAug 09Sale298.541,260376,16010,685Aug 13 04:10 PM
RAGUSA ROBERT PSVP, Global Quality & OpsAug 08Sale293.092,230653,59111,866Aug 12 05:22 PM
deSouza Francis APresident and CEOAug 01Sale301.253,000903,75961,600Aug 05 04:45 PM
Dadswell CharlesSVP & General CounselAug 01Sale300.0012437,2006,606Aug 05 04:40 PM
FLATLEY JAY TDirectorJul 24Sale304.003,3001,003,200269,316Jul 25 05:22 PM
Ronaghi MostafaSVP & CTOJul 15Option Exercise69.3410,000693,40086,776Jul 18 11:38 AM
Ronaghi MostafaSVP & CTOJul 15Sale302.0410,0003,020,39276,776Jul 18 11:38 AM
FLATLEY JAY TDirectorJul 10Sale376.503,3001,242,450272,616Jul 12 06:19 PM
deSouza Francis APresident and CEOJul 01Sale369.553,0001,108,65564,936Jul 03 04:50 PM
Dadswell CharlesSVP & General CounselJul 01Sale371.2912446,0406,679Jul 03 04:47 PM
FLATLEY JAY TDirectorJun 26Sale358.153,3001,181,895275,916Jun 28 04:06 PM
Ronaghi MostafaSVP & CTOJun 17Option Exercise69.3410,000693,40086,776Jun 19 07:07 PM
Ronaghi MostafaSVP & CTOJun 17Sale349.2810,0003,492,75376,776Jun 19 07:07 PM
FLATLEY JAY TDirectorJun 12Sale334.533,3001,103,949279,216Jun 14 04:00 PM
OSTADAN OMEADSVP Mktg, Prod & Strat PlanJun 10Sale335.031,260422,13811,945Jun 12 04:05 PM
deSouza Francis APresident and CEOJun 03Sale309.693,000929,08067,936Jun 05 04:34 PM
Dadswell CharlesSVP & General CounselJun 03Sale309.701,220377,8386,866Jun 05 04:27 PM
FLATLEY JAY TDirectorMay 22Sale304.443,3001,004,652282,516May 24 05:22 PM
Ronaghi MostafaSVP & CTOMay 15Option Exercise69.3410,000693,40087,414May 16 08:34 PM
Ronaghi MostafaSVP & CTOMay 15Sale305.4910,0003,054,87677,414May 16 08:34 PM
ARNOLD FRANCESDirectorMay 13Sale307.951,503462,84910,159May 15 04:44 PM
OSTADAN OMEADSVP Mktg, Prod & Strat PlanMay 10Sale315.321,260397,30313,205May 13 07:42 PM
FLATLEY JAY TDirectorMay 08Sale318.593,3001,051,347285,816May 10 05:50 PM
EPSTEIN ROBERT SDirectorMay 01Option Exercise51.175,000255,8508,256May 03 05:18 PM
EPSTEIN ROBERT SDirectorMay 01Sale310.445,0001,552,1783,256May 03 05:18 PM
deSouza Francis APresident and CEOMay 01Sale310.013,000930,02970,936May 03 05:12 PM
Dadswell CharlesSVP & General CounselMay 01Sale311.7712438,6598,086May 03 05:07 PM
FLATLEY JAY TDirectorApr 24Sale321.963,3001,062,468289,116Apr 26 05:29 PM
FLATLEY JAY TDirectorApr 10Sale317.013,3001,046,133331,668Apr 12 04:33 PM
EPSTEIN ROBERT SDirectorApr 01Option Exercise51.171,00051,1704,256Apr 03 05:28 PM
EPSTEIN ROBERT SDirectorApr 01Sale314.451,000314,4503,256Apr 03 05:28 PM
deSouza Francis APresident and CEOApr 01Sale315.933,000947,78873,746Apr 03 05:25 PM
Dadswell CharlesSVP & General CounselApr 01Sale314.4512438,9928,210Apr 03 05:22 PM
FLATLEY JAY TDirectorMar 27Sale306.933,3001,012,869334,968Mar 29 04:01 PM
FLATLEY JAY TDirectorMar 13Sale306.503,3001,011,450338,268Mar 29 04:01 PM
EPSTEIN ROBERT SDirectorMar 01Option Exercise51.171,00051,1704,256Mar 05 04:57 PM
EPSTEIN ROBERT SDirectorMar 01Sale313.931,000313,9303,256Mar 05 04:57 PM
deSouza Francis APresident and CEOMar 01Sale316.513,000949,51876,746Mar 05 04:58 PM
Dadswell CharlesSVP & General CounselMar 01Sale313.931,220382,9958,334Mar 05 04:56 PM
FLATLEY JAY TDirectorFeb 27Sale300.003,300990,000341,568Mar 01 05:23 PM
Hoyt Aimee LSVP, Chief People OfficerFeb 26Sale304.6329890,7802,297Feb 28 05:30 PM
OSTADAN OMEADSVP Mktg, Prod & Strat PlanFeb 15Sale294.621,260371,21629,420Feb 19 07:02 PM
FLATLEY JAY TDirectorFeb 13Sale293.663,300969,078344,868Feb 14 04:21 PM
Van Oene MarkSVP Chief Commercial OfficerFeb 12Option Exercise0.005,639015,419Feb 14 04:36 PM
Ronaghi MostafaSVP & CTOFeb 12Option Exercise0.009,782079,217Feb 14 04:34 PM
RAGUSA ROBERT PSVP, Global Quality & OpsFeb 12Option Exercise0.004,540015,316Feb 14 04:32 PM
OSTADAN OMEADSVP Mktg, Prod & Strat PlanFeb 12Option Exercise0.009,492033,875Feb 14 04:23 PM
FLATLEY JAY TDirectorFeb 12Option Exercise0.0028,8880358,929Feb 14 04:21 PM
deSouza Francis APresident and CEOFeb 12Option Exercise0.0024,621082,910Feb 14 04:17 PM
Dadswell CharlesSVP & General CounselFeb 12Option Exercise0.004,127011,064Feb 14 04:15 PM
EPSTEIN ROBERT SDirectorFeb 01Option Exercise51.171,00051,1704,256Feb 05 04:45 PM
deSouza Francis APresident and CEOFeb 01Sale282.953,000848,85464,104Feb 05 04:46 PM
EPSTEIN ROBERT SDirectorFeb 01Sale280.111,000280,1103,256Feb 05 04:45 PM
Dadswell CharlesSVP & General CounselFeb 01Sale280.1112434,7346,879Feb 05 04:44 PM
FLATLEY JAY TDirectorJan 23Sale303.533,3001,001,649329,979Jan 25 04:27 PM
FLATLEY JAY TDirectorJan 09Sale296.203,300977,460333,279Jan 11 04:35 PM
EASTHAM KARINDirectorJan 02Option Exercise71.094,000284,36015,838Jan 04 05:03 PM
EPSTEIN ROBERT SDirectorJan 02Option Exercise51.171,00051,1704,256Jan 04 05:05 PM
deSouza Francis APresident and CEOJan 02Sale293.333,000879,99467,104Jan 04 05:04 PM
EASTHAM KARINDirectorJan 02Sale294.085,0001,470,38110,838Jan 04 05:03 PM
EPSTEIN ROBERT SDirectorJan 02Sale294.711,000294,7103,256Jan 04 05:05 PM
Dadswell CharlesSr VP & General CounselJan 02Sale294.7112436,5447,003Jan 04 05:01 PM
FLATLEY JAY TDirectorDec 26Sale273.873,300903,771336,579Dec 28 05:36 PM
FLATLEY JAY TDirectorDec 12Sale334.133,3001,102,629371,559Dec 13 07:26 PM
OSTADAN OMEADEVP Ops, Products, StrategyDec 10Sale321.50644207,04621,613Dec 12 01:59 PM
Stapley MarcEVP Strategy & Corp DevelopmtDec 06Sale329.691,000329,6956,957Dec 07 05:17 PM
EPSTEIN ROBERT SDirectorDec 03Option Exercise51.171,00051,1706,101Dec 04 09:03 PM
EPSTEIN ROBERT SDirectorDec 03Sale343.571,345462,1024,756Dec 04 09:03 PM
Dadswell CharlesSr VP & General CounselDec 03Sale343.57566194,4615,606Dec 04 09:01 PM
deSouza Francis APresident and CEODec 03Sale345.903,0001,037,68863,643Dec 04 09:02 PM
FLATLEY JAY TDirectorNov 28Sale321.803,3001,061,940373,410Nov 30 04:24 PM
OSTADAN OMEADEVP Ops, Products, StrategyNov 23Sale306.74644197,54122,257Nov 27 04:39 PM
FLATLEY JAY TDirectorNov 14Sale312.503,3001,031,250376,710Nov 16 04:09 PM
Ronaghi MostafaSr VP & CTONov 12Option Exercise37.0410,000370,40079,612Nov 14 05:44 PM
Ronaghi MostafaSr VP & CTONov 12Sale314.6310,0003,146,33769,612Nov 14 05:44 PM